Osimertinib, an irreversible third‐generation EGFR‐TKI, has been the standard first‐line treatment for EGFR‐mutated NSCLC since the publication of the FLAURA trial results [1, 2]. Here, EGFR is linked to non-small cell lung carcinoma.